The economics of kidney transplantation versus hemodialysis

Progress in Transplantation

Volumn 11, Issue 4, 2001, Pages 291-297

  Loubeau, P R ^a   Loubeau, J M ^a   Jantzen, R ^a  

^a IONA COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ARTICLE; GRAFT REJECTION; HEALTH CARE COST; HEALTH ECONOMICS; HEMODIALYSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MEDICARE; POSTOPERATIVE COMPLICATION; UNITED STATES;

EID: 0035655746     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/prtr.11.4.n138851n77524hu1     Document Type: Article

References (29)

1. Cyclosporine: 5 Years experience in cadaveric transplantation
2. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants
3. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients
4. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
5. Transplant shortages
6. A study of the quality of life and cost-utility of renal transplantation
7. A survival advantage for renal transplantation
8. Analyzing the cost effectiveness of kidney transplantation
9. Comparison of treatment costs between dialysis and transplantation
10. The shrinking renal replacement therapy "break-even" point
11. Cost issues in transplantation
12. Cadeveric versus living donor kidney transplantation
13. FDA advisory panel backs new kidney transplant drug
14. Trends in end-stage renal disease